This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Drug ETFs Likely Winners of Health Law

NEW YORK ( TheStreet) -- Now that the historic health care bill has been signed into law by President Obama, drugmakers are likely to reap all the benefits and for good reason.

The overhaul of the health care system likely will add to the revenue of Big Pharma companies. From a mere quantity perspective, the reform is expected to provide insurance coverage to more individuals, hence giving more people the ability to pay for prescription medication and pushing sales volumes up significantly.

From a competition perspective, it appears that the pharmaceutical sector has won nearly a decade of protection against generic competition for biotech drugs. Additionally, the law doesn't contain any measure which bars the sector from paying generic drugmakers to delay the launch of less-expensive alternatives. In essence, cash heavy pharmaceutical firms have the ability to pay off more cost effective competitors who manufacture "knock-off" alternatives and control the prescription drug market.

Another potential victory can be seen through the scrub of measures which could have potentially eaten away at revenue generated from drug sales to the elderly. More specifically, the law doesn't include any measures which would enable the government to dictate and negotiate the price of drugs sold through Medicare Part D, which for some pharmaceutical companies can comprise nearly 25% of all revenue.

Lastly, the new piece of legislation is anticipated to close the gap in Medicare drug coverage known as the doughnut hole, which forces elderly patients to pay for prescription drugs through the implementation of a discount program. This concession is expected to benefit pharmaceutical companies by enticing elderly users to stay around as opposed to them not taking their medicine or switching to lower-price generics because of cost constraints and affordability.

With this in mind, some equities likely to be influenced by the law include:
  • PowerShares Dynamic Pharmaceuticals(PJP), which boasts biopharmaceutical giants Merck(MRK - Get Report) and Gilead Sciences(GILD - Get Report). PJP closed at $20.35 on Tuesday.
  • iShares Dow Jones US Pharmaceuticals(IHE), which holds pharmaceutical giants Pfizer(PZE) and Johnson & Johnson(JNJ - Get Report) as top holdings. These two companies are especially likely to reap the benefits of this new law. IHE closed at $60.96 on Tuesday.
  • SPDR S&P Pharmaceuticals(XPH), which holds diversified health care companies like ViroPharma(VPHM) and Perrigo(PRGO - Get Report). XPH closed at $42.79 on Tuesday.

Although a rosy picture lies ahead for the sector, it is important to consider the inherent risk involved with investing in equities. A good way to mitigate these risks is through the implementation of an exit strategy which triggers price points at which an upward trend could potentially be coming to an end.

Written by Kevin Grewal in Laguna Niguel, Calif.

At the time of publication, Grewal had no positions in the securities mentioned.
Kevin Grewal serves as the editorial director and research analyst at The ETF Institute, which is the only independent organization providing financial professionals with certification, education, and training pertaining to exchange-traded funds (ETFs). Additionally, he serves as the editorial director at where he focuses on mitigating risks and implementing exit strategies to preserve equity. Prior to this, Grewal was an analyst at a small hedge fund where he constructed portfolios dealing with stock lending, exchange-traded funds, arbitrage mechanisms and alternative investments. He is an expert at dealing with ETFs and holds a bachelor's degree from the University of California along with a MBA from the California State University, Fullerton.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VPHM $49.96 -0.02%
GILD $89.00 0.00%
JNJ $112.75 0.00%
IHE $141.98 0.00%
MRK $55.30 0.00%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs